Ibogaine is classified as a controlled substance in Italy under national narcotics legislation, making its possession, sale, and use illegal outside of explicitly authorized research contexts. Last verified: April 22, 2026.

Current Legal Status

In Italy, ibogaine is listed as a Table I (Tabella I) substance under Decreto del Presidente della Repubblica (DPR) n. 309 del 9 ottobre 1990, the consolidated act on narcotic and psychotropic substances (Testo Unico sugli stupefacenti). Table I represents the most restrictive scheduling tier, grouping ibogaine alongside substances deemed to have high abuse potential and no recognized medical use within the Italian regulatory framework.

Under DPR 309/1990, unauthorized possession, distribution, production, import, or export of Table I substances is a criminal offense. Penalties vary based on quantity and intent:

  • Personal use quantities: Administrative sanctions, mandatory treatment referral, and potential suspension of documents such as a driver's license. Criminal charges are less common for first-time, small-quantity possession.
  • Trafficking or supply: Criminal prosecution under Articles 73 and 74 of DPR 309/1990, carrying prison sentences ranging from 6 to 20 years depending on aggravating factors.

There are no religious exemptions or carve-outs for ibogaine use in Italy, unlike the limited protections that exist in some jurisdictions for ayahuasca used in specific religious contexts. Similarly, there are no approved therapeutic protocols for ibogaine administration under the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA), and it holds no marketing authorization as a medicinal product in Italy or at the European Medicines Agency (EMA) level.

Research exemptions exist in theory: Italian law permits the use of controlled substances for scientific research under strictly authorized conditions overseen by the Ministry of Health and AIFA. However, no publicly known clinical trials involving ibogaine have been actively recruiting in Italy in recent years, and such exemptions do not create any pathway for clinical or therapeutic use outside of a formally approved trial protocol.

Important: Italy's scheduling of ibogaine under Table I means there is no legal gray area for personal therapeutic use, harm reduction contexts, or retreat settings within Italian territory. Any administration would constitute a criminal act under current law.

Treatment Centers

There are no licensed ibogaine treatment centers operating within Italy. Because ibogaine is a Table I controlled substance, no clinic, wellness center, or medical facility can legally administer it on Italian soil. Any facility claiming to offer ibogaine treatment within Italy would be operating unlawfully and should be approached with extreme caution.

Italians seeking ibogaine-assisted treatment typically travel abroad to jurisdictions where ibogaine is legal or unscheduled — most commonly Portugal, the Netherlands, Mexico, or certain clinics in Central America. For a full directory of legally operating ibogaine clinics in other countries, see our ibogaine clinic directory.

How People Access Ibogaine in Italy

The following reflects documented patterns of access and is provided for informational purposes only. None of these avenues are legal within Italy, and this section does not constitute a recommendation.

  • Medical tourism: The most common route for Italians seeking ibogaine is traveling to a country where it is legally available. Portugal — given its geographic proximity, shared EU travel zone, and established cluster of ibogaine clinics operating under medical supervision — is frequently chosen. The Netherlands and Mexico are also common destinations.
  • Underground or informal networks: Anecdotal reports indicate that ibogaine circulates in informal harm reduction and addiction recovery circles within Italy, facilitated through online communities. Such use carries serious legal and medical risks.
  • Research participation: In theory, individuals could enroll in a foreign clinical trial. Italian residents have participated in research conducted in other EU member states, though this requires meeting specific eligibility criteria set by the trial protocols.
  • Importation: Attempting to import ibogaine into Italy — whether personally or via mail — constitutes a serious criminal offense under DPR 309/1990 and EU customs regulations, with potential prosecution for trafficking depending on quantity.

Recent Legal Developments

As of 2026, Italy has not undertaken any legislative or regulatory reform specific to ibogaine. However, the broader psychedelic policy landscape in Europe is shifting, and Italy is monitoring these developments:

  • EU-level discourse: The European Medicines Agency and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, now the European Union Drugs Agency, EUDA) have published reports acknowledging the potential therapeutic applications of psychedelic substances including ibogaine for opioid use disorder. These reports inform national policy conversations but have not yet triggered scheduling reviews in Italy.
  • MAPS and global trial data: Results from international phase 2 and phase 3 trials of psychedelic-assisted therapies — while primarily focused on MDMA and psilocybin — have prompted Italian addiction medicine specialists and psychiatric associations to discuss the evidence base for ibogaine in opioid detoxification. No formal proposal to reschedule ibogaine has been introduced in the Italian Parliament as of this writing.
  • Psilocybin policy signals: Italy's cautious interest in therapeutic psilocybin research, reflected in early-stage academic discussions, suggests any future ibogaine reform would follow a research-first, gradual pathway similar to other EU member states rather than broad decriminalization.
  • Drug policy reform advocacy: Italian civil society organizations, including harm reduction groups such as Forum Droghe, have advocated for broader decriminalization approaches, though ibogaine has not been a central focus of domestic advocacy campaigns.
No imminent reform: Despite evolving global attitudes, there is no pending Italian legislation that would reschedule, decriminalize, or create therapeutic access pathways for ibogaine in the near term.

Risks of Seeking Treatment in Italy

Because no legal framework supports ibogaine use in Italy, individuals who pursue it domestically face layered risks that extend beyond the known pharmacological dangers of the substance itself:

  • Criminal exposure: Possession of ibogaine in Italy can result in administrative sanctions or criminal prosecution. Being found in possession — even with clear personal-use intent — creates a permanent legal record that may affect employment, travel, and professional licensing.
  • No quality control: Ibogaine obtained through informal channels has no regulatory oversight. Adulterants, incorrect dosing, or misidentified plant material (e.g., confusion between ibogaine HCl, total alkaloid extract, and raw Tabernanthe iboga root bark) significantly elevate cardiac and neurological risk.
  • No medical safety net: Underground settings in Italy cannot provide cardiac monitoring, resuscitation equipment, or emergency protocols required for safe ibogaine administration. Ibogaine carries a documented risk of potentially fatal cardiac arrhythmia, including QTc prolongation and torsades de pointes. Without pre-screening and medical supervision, this risk is substantially elevated.
  • No legal recourse: Individuals harmed in an unauthorized ibogaine setting have limited legal recourse, as the activity itself is illegal. Practitioners operating underground cannot be held to any standard of care through civil or regulatory channels.
  • Psychosocial risks: Without trained integration support, which licensed clinicians in legal jurisdictions typically provide, individuals may face unresolved psychological material following a powerful ibogaine experience.

Frequently Asked Questions

No. Ibogaine is a Table I controlled substance under DPR 309/1990, Italy's consolidated narcotics law. Its possession, use, sale, and import are illegal without specific ministerial authorization for research purposes. There is no therapeutic or personal-use exemption under Italian law.
Penalties depend on quantity and intent. Personal-use possession may result in administrative sanctions (such as suspension of a driver's license or passport) and compulsory referral to treatment services rather than imprisonment, under Articles 75 and 121 of DPR 309/1990. However, possession of larger quantities or any evidence of supply or trafficking can result in criminal charges carrying 6–20 years of imprisonment. The distinction between personal use and trafficking is determined by the threshold quantities set by ministerial decree, which are periodically revised.
Italian law does not explicitly criminalize seeking drug treatment in a foreign country where that treatment is legal. Many Italians travel to countries such as Portugal or the Netherlands, where ibogaine is legally available at licensed clinics. However, attempting to bring ibogaine back into Italy is illegal and constitutes importation of a Table I controlled substance. You should consult with a qualified attorney regarding your individual circumstances before making any decisions.
Currently there are no publicly known, actively recruiting clinical trials investigating ibogaine in Italy. Italian academic institutions have published theoretical and review literature on ibogaine's anti-addictive mechanisms, but translating this into approved human trials would require AIFA authorization and Ministry of Health approval under a strict regulatory process. Monitoring the ClinicalTrials.gov registry and the EU Clinical Trials Register (EUCTR) is the best way to track any future Italian research activity.
There is no pending legislation or regulatory proposal to reschedule ibogaine in Italy as of April 2026. Italy's drug policy has historically been conservative relative to some other EU member states. While the global conversation around psychedelic medicine is influencing Italian academic and clinical circles, meaningful regulatory reform — if it occurs — is likely years away and would most plausibly begin with approved research exemptions rather than broad rescheduling.
Yes. Italian law controls ibogaine as the active substance, and this scheduling extends to preparations, extracts, and plant material containing ibogaine or its salts. Possession of Tabernanthe iboga root bark with the intent to extract or consume ibogaine would fall under DPR 309/1990 Table I restrictions. The botanical plant itself is not explicitly listed as a separately scheduled species, but because the controlled substance is present in the plant material, enforcement treats such possession as equivalent to possessing the controlled substance.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.